Main Navigation

Language Selector

    Innovative Medicines Initiative

    Joint Technology Initiative - IMI2

    The Innovative Medicines Initiative 2 (IMI2) is a Public-Private Partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), and starts in 2014.

    IMI 2 will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.



    IMI 2 will provide Europeans, including the increasing numbers of older people, with more efficient and effective medicines and treatments.
    In particular, IMI 2 aims to deliver:

    • a 30% better success rate in clinical trials of priority medicines identified by the WHO;
    • clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in just five years;
    • new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease

    Scientific Disciplines

    • Life Sciences
    • Medicine & Pharmaceutics
    • Public Health
    • Biological Sciences
    • Measures & Standards

    Industrial Sectors

    • Human Health
    • Biostatistics
    • Care & Health Services
    • Clinical Research
    • Oncology
    • Diagnostics
    • Diseases
    • Gerontology / Geriatrics
    • Heart & Blood Circulation Illnesses
    • Neurology / Brain Research
    • Pharmaceuticals / Drugs
    • Biology / Biotechnology
    • Genome Research

    Main Target Audience

    • Universities / UAS
    • Research institutes
    • SMEs
    • Pharma Industry
    • Hospitals
    • Patient organisations
    • CROs

    Key Information

    Duration of the programme: 2014-2024
    Topics: all biomedical fields
    Total budget: €2.45 billion; typical project budget is €10-20 million for 5 years
    Funding: partly by the European Union, partly by EFPIA
    Swiss eligibility: tbc, for additional information visit the FAQ on Switzerland as 3rd country:
    FAQ on Swiss Industrialised Third Country Participation in Horizon 2020
    Calls for proposals: several calls per year expected
    Rules for participation: consortium composed of at least 2 legal entities (no EFPIA members but they may join later) located in an EU Member State or Horizon 2020 Associated Country; typically approx. 20 partners (of which approx. 8 EFPIA members)

    Your Contact

    State Secretariat for Education,
    Research and Innovation SERI

    Dr. Isabella Beretta
    Effingerstrasse 27, 3003 Bern
    Tel. +41 31 322 84 17